NDAQ:BFRI Forum Post | PressRelease-35088684 | New Press Release - Biofrontera Inc. to Report Third Quarter Financial Results on November 14, 2022 | Biofrontera Inc (2024)

Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.

I Agree

×

Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Please Try Again {{ error }}

Send my password

SUCCESS

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

NDAQ:BFRI Forum Post | PressRelease-35088684 | New Press Release - Biofrontera Inc. to Report Third Quarter Financial Results on November 14, 2022 | Biofrontera Inc (2)

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Linking with Facebook:

Stockhouse membership requires an email address which must be shared by Facebook.

By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.

If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.

Please do not modify the permission settings during sign-in.

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Healthcare

Biofrontera Inc. is a biopharmaceutical company. The Company is focused on commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company’s licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its principal licensed product is Ameluz, which is a prescription drug for use in combination with the BF-RhodoLED lamp series, for photodynamic therapy. In the United States, the PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses (AK) of mild-to-moderate severity on the face and scalp. The Company’s other products include Xepi for the treatment of impetigo, a common skin infection, due to Staphylococcus aureus or Streptococcus pyogenes. It is used in the United States in adults and children two months and older.



No Data Exists for symbol: BFRI

{data.pricedata.last | asQHLast tLang} {data.pricedata.last | asQHLast tLang | asCurrency data.key.currency tLang} {data.pricedata.change | asQHLast tLang } | {data.pricedata.changepercent | numeraljs '0.00' | postFix '%' tLang} {data.status.regsho} {data.status.halt.code} {tplLang.bid| toLang tLang}: {data.pricedata.bid | asQHLast tLang} x {data.pricedata.bidsize} {tplLang.ask| toLang tLang}: {data.pricedata.ask | asQHLast tLang} x {data.pricedata.asksize} Volume: {data.pricedata.sharevolume | numeraljs '0,0' 'N/A' tLang} Volume: {data.pricedata.sharevolume | numeraljs '0,0' '0' tLang}

{tplLang.low| toLang tLang}: {data.pricedata.low | asQHLast tLang} | {tplLang.high| toLang tLang}: {data.pricedata.high | asQHLast tLang} | {tplLang.yearlow|toLang tLang}: {data.fundamental.week52low.content | asQHLast tLang} | {tplLang.yearhigh|toLang tLang}: {data.fundamental.week52high.content | asQHLast tLang}

{tplLang.afterhours| toLang tLang} {data.afterhours.change | asQHLast tLang } | {data.tz | asTimezone tLang} Volume: {data.afterhours.sharevolume | numeraljs '0,0' 'N/A' tLang}

{data.tz | asTimezone tLang}

New Post

NDAQ:BFRI - Post by User

Biofrontera Inc

<< Previous

Bullboard Posts

Next >>

Post by PressReleaseon Nov 10, 2022 11:53am

NDAQ:BFRI Forum Post | PressRelease-35088684 | New Press Release - Biofrontera Inc. to Report Third Quarter Financial Results on November 14, 2022 | Biofrontera Inc (10)139 Views

Post# 35088684

New Press Release - Biofrontera Inc. to Report Third Quarter Financial Results on November 14, 2022

WOBURN, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three and nine months ended September 30, 2022 before the opening of...read article.

Comment on this Post

<< Previous

Bullboard Posts

Next >>

Thank You
Your Report has been submitted.

Report Abusive Content

Sign up to get access

You are already a member! Please enter your password to sign in.

Forgot password?

Back

By providing my email, I consent to receiving messages from Stockhouse.

{{ dialogTitle }}

{{reasonError}}

{{feedbackError}}

{{submitMsg}}

NDAQ:BFRI Forum Post | PressRelease-35088684 | New Press Release - Biofrontera Inc. to Report Third Quarter Financial Results on November 14, 2022 | Biofrontera Inc (16)

Interested in these industries and sectors?

Receive investor kits and email updates from Stockhouse and directly from these companies.

Healthcare

All None

Energy

All None

Consumer Cyclical

All None

Metals & Mining

All None

Industrials

All None

Communication Services

All None

Utilities

All None

You are already a member! Please enter your password to sign in.

Forgot password?

Back

I consent to receiving investment related electronic messages from Stockhouse and the companies selected. I may withdraw my consent at any time.


NDAQ:BFRI Forum Post | PressRelease-35088684 | New Press Release - Biofrontera Inc. to Report Third Quarter Financial Results on November 14, 2022 | Biofrontera Inc (2024)

References

Top Articles
Latest Posts
Recommended Articles
Article information

Author: Gov. Deandrea McKenzie

Last Updated:

Views: 5626

Rating: 4.6 / 5 (46 voted)

Reviews: 93% of readers found this page helpful

Author information

Name: Gov. Deandrea McKenzie

Birthday: 2001-01-17

Address: Suite 769 2454 Marsha Coves, Debbieton, MS 95002

Phone: +813077629322

Job: Real-Estate Executive

Hobby: Archery, Metal detecting, Kitesurfing, Genealogy, Kitesurfing, Calligraphy, Roller skating

Introduction: My name is Gov. Deandrea McKenzie, I am a spotless, clean, glamorous, sparkling, adventurous, nice, brainy person who loves writing and wants to share my knowledge and understanding with you.